Regulation of airway mucosal hydration

Expert Review of Clinical Pharmacology

Volumn 3, Issue 3, 2010, Pages 361-369

  Paisley, Derek ^a   Gosling, Martin ^a   Danahay, Henry ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Airway epithelium; Cystic fibrosis; Hydration; Ion channel

Indexed keywords

552 02; AER 002; AMILORIDE; ATALUREN; BAY 39 9437; CAMOSTAT; DENUFOSOL; EPITHELIAL SODIUM CHANNEL; GENTAMICIN; GS 9411; INO 4995; ION CHANNEL; LANCOVUTIDE; NVP QAU 145; P 552 02; P 680; PLACEBO; RESPIRATORY TRACT AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR; ULINASTATIN; UNCLASSIFIED DRUG; VX 770; VX 809;

CHANNEL GATING; CHLORIDE CONDUCTANCE; CHLORIDE TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE MUTATION; HUMAN; HYDRATION; MAXIMAL MID EXPIRATORY FLOW; MUCOCILIARY CLEARANCE; MUCUS SECRETION; MULTIPLE CYCLE TREATMENT; NONHUMAN; RECURRENT INFECTION; REGULATORY MECHANISM; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 77952570154     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.19     Document Type: Review

References (78)

1. Boucher RC. Human airway ion transport: part one. Am. J. Respir. Crit. Care Med. 150, 271-281 (1994).
2. Boucher RC. Human airway ion transport: part two. Am. J. Respir. Crit Care Med. 150, 581-593 (1994).
3. Lai-Fook SJ. Mechanics of lung fluid balance. Crit. Rev. Biomed. Eng. 13 (3), 171-200 (1986).
4. Dobbs LG, Johnson MD. Alveolar epithelial transport in the adult lung. Respir. Physiol. Neurobiol. 159 (3), 283-300 (2007).
5. Wanner A, Salathé M, O'Riordan TG. Mucociliary clearance in the airways. Am. J. Respir. Crit. Care Med. 154 (6 Pt 1), 1868-902 (1996).
6. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med. 261 (1), 5-16 (2007). • Reviews data supporting the 'low-volume' hypothesis for cystic fibrosis.
7. Potter JL, Matthews LW, Spector S, Lemm J. Studies of pulmonary secretions. II. Osmolarity and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am. Rev. Respir. Dis. 96, 83-87 (1967).
8. + channel (ENaC) loss-of-function mutations.
9. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 153, 1503-1509 (1996).
10. Robinson M, Daviskas E, Eberl S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 14 (3), 678-685 (1999).
11. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr. Pulmonol. 21, 77-83 (1996).
12. Jaques A, Daviskas E, Turton JA et al Inhaled mannitol improves lung function in cystic fibrosis. Chest 133 (6), 1388-1396 (2008).
13. Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. National Hypertonic Saline in Cystic Fibrosis (NHSCF) study group. N. Engl. J. Med. 354 (3), 229-240 (2006). • Important clinical proof of concept for improving airway hydration in cystic fibrosis.
14. Bilton D, Robinson P, Cooper P, Charlton B. Randomized, double blind, placebo controlled Phase III study of inhaled dry powder mannitol (bronchitol) in CF. Pediatr. Pulmonol. 44 (Suppl. 32), 286 (2009).
15. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245 (4922), 1059-1065 (1989).
16. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (4922), 1066-1073 (1989).
17. Rosenecker J, Huth S, Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr. Opin. Mol. Ther. 8 (5), 439-445 (2006).
18. Oette S, Gedeon CR, Kowalczyk TH et al. Aerosols of compacted DNA nanoparticles retain structural integrity and biological activity. Mol. Ther. 9, S190-S190 (2004).
19. Alton EW, Stern M, Farley R et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353 (9157), 947-954 (1999).
20. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358 (6389), 761-764 (1992).
21. Dalemans W, Barbry P, Champigny G et al. Altered chloride ion channel kinetics associated with the δ F508 cystic fibrosis mutation. Nature 354 (6354), 526-528 (1991).
22. Van Goor F, Straley KS, Cao D et al. Rescue of δF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (6), L1117-L1130 (2006).
23. Van Goor F, Hadida S, Grootenhuis PD et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106 (44), 18825-18830 (2009). • Overview of key in vitro data supporting VX-770.
24. Boyle M, Clancy JP, Rowe SM et al. Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation. Pediatr. Pulmonol. 44 (Suppl. 32), 287 (2009).
25. Accurso F, Rowe SM, Durie PR et al. Improvement in sweat chloride concentration by the CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation. Pediatr. Pulmonol. 44 (Suppl. 32), 296 (2009).
26. Clancy JP, Rowe SM, Durie P et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatr. Pulmonol. 44 (Suppl. 32), 288-289 (2009).
27. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154 (5), 1229-1256 (1996).
28. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361 (9370), 1671-1676 (2003).
29. Noone PG, Pue CA, Zhou Z et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am. J. Respir. Crit. Care Med. 162 (5), 1919-1924 (2000).
30. Noone PG, Zhou Z, Silverman LM, Jowell PS, Knowles MR, Cohn JA. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 121 (6), 1310-1309 (2001).
31. Van Goor F, Hadida S, Grootenhuis PD et al. VX-809, a CFTR corrector, increases the cell surface density of functional F508del-CFTR in pre-clinical models of cystic fibrosis. Pediatr. Pulmonol 44 (Suppl. 32), 154 (2009)
32. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat. Rev. Drug Discov. 8 (2), 153-171 (2009).
33. Clancy JP, Bebök Z, Ruiz F et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163 (7), 1683-1692 (2001).
34. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC 124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372 (9640), 719-727 (2008).
35. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic disease. Trends Genet. 24 (11), 552-563 (2008).
36. Boucher RC, Cheng EH, Paradiso AM, Stutts MJ, Knowles MR, Earp HS. Chloride secretory response of cystic fibrosis human airway epithelia. Preservation of calcium but not protein kinase C- and A-dependent mechanisms. J. Clin. Invest. 84 (5), 1424-1431 (1989).
37. Anderson MP, Welsh MJ. Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia. Proc. Natl Acad. Sci. USA 88 (14), 6003-6007 (1991).
38. 2 agonist denufosol.
39. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325 (8), 533-538 (1991).
40. Paradiso AM, Ribeiro CMP, Boucher RC. Polarized signaling via purinoceptors in normal and cystic fibrosis airway epithelia. J. Gen. Physiol. 117 (1), 53-67 (2001).
41. Yerxa BR, Sabater JR, Davis CW et al. Pharmacology of INS37217 [P (1) - (uridine 5) -P (4) - (2'-deoxycytidine 5) tetraphosphate, tetrasodium salt], a nextgeneration P2Y (2) receptor agonist for the treatment of cystic fibrosis. J. Pharmacol Exp. Ther. 302 (3), 871-880 (2002).
42. 2 receptor agonist, in patients with mild to moderate cystic fibrosis: results of a Phase 2 multi-center study. Pediatr. Pulmonol. 38 (S27), 249 (2004).
43. 2 receptor agonist: results of a Phase 1/Phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr. Pulmonol 39 (4), 339-348 (2005).
44. Smiley L, Rossi A, Matthews D et al. Denufosol tetrasodium inhalation solution: results from two Phase 2 trials in CF patients with mild to moderate lung disease. J. Cyst. Fibros. 5 (Suppl. 1), S11 (2006).
45. Accurso F. The TIGER-1 Phase 3 clinical trial of denufosol for cystic fibrosis. Pediatr. Pulmonol. 44 (S31), 191 (2008).
46. Hartzell C, Putzier I, Arreola J. Calciumactivated chloride channels. Annu. Rev. Physiol. 67, 719-758 (2005).
47. Caputo A, Caci E, Ferrera L et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322 (5901), 590-594 (2008).
48. Schroeder BC, Cheng T, Jan YN, Jan LY. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134 (6), 1019-1029 (2008).
49. Yang YD, Cho H, Koo JY et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455 (7217), 1210-1215 (2008).
50. 2+-dependent chloride transport. J. Biol. Chem. 284 (42), 28698-28703 (2009).
51. Rock JR, Futtner CR, Harfe BD. The transmembrane protein TMEM16A is required for normal development of the murine trachea. Dev. Biol. 321 (1), 141-149 (2008).
52. Namkung W, Carpenter RD, Verkman AS. Small-molecule activators and inhibitors of calcium-activated chloride channel TMEM16A. Pediatr. Pulmonol. 44 (S32), 288 (2009).
53. Grasemann H, Stehling F, Brunar H. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131 (5), 1461-1466 (2007).
54. Eber E, Trawinska-Bartnicka M, Sands DA et al. A randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of aerosolized lancovutide (moli1901) in adolescents (12 years of age or older) and adults with CF. Pediatr. Pulmonol. 44 (S32), 302 (2009).
55. + transport and improves fluid dynamics in cystic fibrosis airway epithelia. Am. J. Physiol. Cell Physiol. 289 (3), C512-C520 (2005).
56. Traynor-Kaplan AE, Moody M, Nur M et al. INO-4995 therapeutic efficacy is enhanced with repeat dosing in CF KO mice and human epithelia. Am. J. Respir. Cell Mol. Biol. 42 (1), 105-112 (2010).
57. Firsov D, Gautschi I, Merillat AM, Rossier BC, Schild L. The heterotetrameric architecture of the epithelial sodium channel (ENaC). EMBO J. 17 (2), 344-352 (1998).
58. + channel mechanism revealed by the acid-sensing ion channel 1 structure. IUBMB Life 60 (9), 620-628 (2008).
59. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10 (5), 487-493 (2004). • β-ENaC overexpressing transgenic mouse with CF-like lung phenotype.
60. Zhou Z, Treis D, Schubert SC et al Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC- overexpressing mice. Am. J. Respir. Crit. Care Med. 178 (12), 1245-1256 (2008).
61. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am. Rev. Respir. Dis. 124 (4), 484-490 (1981).
62. Middleton PG, Geddes DM, Alton EW Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur. Respir. J. 7 (11), 2050-2056 (1994).
63. Fajac I, Hubert D, Guillemot D et al. Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients. Thorax 59 (11), 971-976 (2004).
64. App EM, King M, Helfesrieder R, Köhler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am. Rev. Respir. Dis. 141 (3), 605-612 (1990).
65. Köhler D, App E, Schmitz-Schumann M, Würtemberger G, Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur. J. Respir. Dis. Suppl. 146, 319-326 (1986).
66. Knowles MR, Church NL, Waltner WE et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med. 322 (17), 1189-1194 (1990).
67. Pons G, Marchand MC, d'Athis P et al. French multicenter randomized doubleblind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr. Pulmonol. 30 (1), 25-31 (2000).
68. Bowler IM, Kelman B, Worthington D et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch. Dis. Child 73 (5), 427-430 (1995).
69. Graham A, Hasani A, Alton EW et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J. 6 (9), 1243-1248 (1993).
70. Noone PG, Regnis JA, Liu X et al. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 112 (5), 1283-1290 (1997).
71. + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (1), L16-L23 (2001).
72. Vallet V, Chraibi A, Gaeggeler HP, Horisberger JD, Rossier BC. An epithelial serine protease activates the amiloridesensitive sodium channel. Nature 389 (6651), 607-610 (1997). • Identification of a channel activating protease involved in regulating ENaC activity.
73. Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC, Gabriel SE. Regulation of the epithelial sodium channel by serine proteases in human airways. J. Biol. Chem. 277 (10), 8338-8345 (2002).
74. Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 294 (5), L932-L941 (2008).
75. Coote K, Atherton-Watson HC, Sugar R et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J. Pharmacol. Exp. Ther. 329 (2), 764-774 (2009).
76. Rowe SM, Reeves G, Young H et al. Correction of sodium transport with nasal administration of the prostasin inhibitor QAU145 in CF subjects. Pediatr. Pulmonol. 44 (S32), 295 (2009).
77. Wang X, Venable J, LaPointe P et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127 (4), 803-815 (2006).
78. Hutt DM, Herman D, Rodrigues AP et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6 (1), 25-33 (2010).